%	O
%	O
TITLE	O

Role	O
of	O
high	O
-	O
risk	O
human	O
papillomavirus	O
in	O
the	O
etiology	O
of	O
oral	O
and	O
oropharyngeal	O
cancers	O
in	O
Thailand	B-Study_Location
:	O
A	O
case	O
-	O
control	O
study	O
.	O

%	O
%	O
ABSTRACT	O

Among	O
developing	O
countries	O
,	O
Thailand	B-Study_Location
shows	O
no	O
increase	O
in	O
the	O
incidence	B-Incidence_or_Prevalence
of	O
human	O
papillomavirus	O
-	O
driven	O
oropharyngeal	O
cancer	O
.	O

The	O
causal	O
role	O
of	O
human	O
papillomavirus	O
infection	O
in	O
this	O
pathology	O
has	O
not	O
been	O
researched	O
thoroughly	O
.	O
A	O
hospital	O
-	O
based	O
,	O
case	B-HPV_Sample_Type
-	I-HPV_Sample_Type
control	I-HPV_Sample_Type
study	I-HPV_Sample_Type
was	O
performed	O
which	O
included	O
104	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
newly	I-Study_Cohort
diagnosed	I-Study_Cohort
oral	I-Study_Cohort
and	I-Study_Cohort
oropharyngeal	I-Study_Cohort
squamous	I-Study_Cohort
cell	I-Study_Cohort
carcinomas	I-Study_Cohort
and	I-Study_Cohort
104	I-Study_Cohort
individuals	I-Study_Cohort
without	I-Study_Cohort
cancer	I-Study_Cohort
.	I-Study_Cohort

The	O
Cervista	O
high	O
-	O
risk	O
human	O
papillomavirus	O
and	O
16	O
/	O
18	O
assays	O
were	O
used	O
to	O
detect	O
human	O
papillomavirus	O
.	O

Odds	O
ratios	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
high	O
-	O
risk	O
genotypes	O
of	O
human	O
papillomavirus	O
and	O
the	O
cancers	O
.	O
High	O
-	O
risk	O
human	O
papillomavirus	O
was	O
detected	O
in	O
4	O
of	O
52	O
(	O
7	O
.	O
7	O
%	O
)	O
oral	O
cancer	O
cases	O
,	O
6	O
of	O
52	O
(	O
11	O
.	O
5	O
%	O
)	O
oropharyngeal	O
cancer	O
cases	O
,	O
and	O
1	O
of	O
104	O
(	O
0	O
.	O
96	O
%	O
)	O
control	O
subjects	O
.	O

Of	O
104	O
cancer	O
patients	O
in	O
the	O
study	O
,	O
83	O
were	O
smokers	O
.	O

High	O
-	O
risk	O
human	O
papillomavirus	O
was	O
significantly	O
associated	O
with	O
oropharyngeal	O
cancer	O
(	O
odds	O
ratioâ€‰=â€‰13	O
.	O
44	O
,	O
95	O
%	O
confidence	O
intervalâ€‰=â€‰1	O
.	O
6	O
-	O
114	O
.	O
8	O
)	O
but	O
was	O
nonsignificantly	O
associated	O
with	O
oral	O
cancer	O
(	O
odds	O
ratioâ€‰=â€‰8	O
.	O
58	O
,	O
95	O
%	O
confidence	O
intervalâ€‰=â€‰0	O
.	O
9	O
-	O
78	O
.	O
9	O
)	O
.	O

However	O
,	O
after	O
adjustment	O
for	O
smoking	O
,	O
high	O
-	O
risk	O
human	O
papillomavirus	O
was	O
determined	O
to	O
be	O
nonsignificantly	O
associated	O
with	O
oropharyngeal	O
cancer	O
(	O
adjusted	O
odds	O
ratioâ€‰=â€‰5	O
.	O
83	O
,	O
95	O
%	O
confidence	O
intervalâ€‰=â€‰0	O
.	O
8	O
-	O
43	O
.	O
5	O
)	O
.	O
Although	O
low	O
human	O
papillomavirus	O
prevalence	B-Incidence_or_Prevalence
was	O
observed	O
,	O
the	O
rate	O
of	O
high	O
-	O
risk	O
human	O
papillomavirus	O
infection	O
in	O
the	O
cancer	O
group	O
was	O
still	O
higher	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

Smoking	O
may	O
have	O
an	O
influence	O
on	O
the	O
etiology	O
of	O
human	O
papillomavirus	O
-	O
related	O
cancers	O
.	O

However	O
,	O
the	O
study	O
is	O
underpowered	O
to	O
clarify	O
the	O
role	O
of	O
human	O
papillomavirus	O
as	O
the	O
independent	O
risk	O
factor	O
for	O
oral	O
and	O
oropharyngeal	O
cancers	O
in	O
the	O
Thai	O
population	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Study	O
design	O
and	O
data	O
collection	O

This	O
case–control	B-Study_Type
study	I-Study_Type
was	O
conducted	O
at	O
Chonburi	O
and	O
Lopburi	O
cancer	O
hospitals	O
.	O

These	O
hospitals	O
have	O
been	O
assigned	O
as	O
referral	O
centers	O
for	O
cancer	O
patients	O
from	O
20	O
provinces	O
in	O
Eastern	B-Study_Location
and	I-Study_Location
Central	I-Study_Location
Thailand	I-Study_Location
.	I-Study_Location

Patients	O
were	O
nonrandomly	O
enrolled	O
.	O

The	O
following	O
inclusion	O
criteria	O
were	O
used	O
:	O
a	O
new	O
diagnosis	O
of	O
oral	O
or	O
oropharyngeal	O
can	O
-	O
cer	O
,	O
Thai	O
nationality	O
,	O
and	O
histological	O
features	O
of	O
squamous	O
cell	O
carcinoma	O
.	O

Patients	O
with	O
lip	O
cancers	O
and	O
cancers	O
with	O
-	O
out	O
clearly	O
demarcated	O
tumor	O
epicenter	O
were	O
excluded	O
.	O

Ethical	O
approval	O
for	O
the	O
study	O
was	O
granted	O
by	O
the	O
respec	O
-	O
tive	O
hospital	O
ethics	O
committees	O
.	O

All	O
study	O
participants	O
pro	O
-	O
vided	O
informed	O
consent	O
prior	O
to	O
their	O
enrollment	O
in	O
this	O
study	O
.	O

Sample	O
size	O
calculation	O

The	O
sample	O
requirement	O
for	O
this	O
case–control	O
study	O
was	O
cal	O
-	O
culated	O
using	O
Epi	O
Infotm	O
version	O
7	O
.	O
2	O
.	O
1	O
.	O

0	O
(	O
Division	O
of	O
Health	O
Informatics	O
and	O
Surveillance	O
,	O
Center	O
for	O
Surveillance	O
,	O
Epidemiology	O
and	O
Laboratory	O
Services	O
,	O
Atlanta	O
,	O
GA	O
)	O
.	O

The	O
software	O
requires	O
as	O
inputs	O
the	O
estimated	O
HPV	O
infection	O
rates	O
of	O
cases	O
and	O
control	O
subjects	O
.	O

Because	O
no	O
HPV	O
study	O
in	O
Thailand	B-Study_Location
with	O
comparable	O
HPV	O
testing	O
methods	O
was	O
con	O
-	O
ducted	O
,	O
the	O
assumed	O
HPV	O
infection	O
rates	O
were	O
based	O
from	O
data	O
in	O
other	O
countries	O
.	O

We	O
estimated	O
the	O
presence	O
of	O
HPV	O
infection	O
to	O
be	O
at	O
least	O
20	O
%	O
in	O
patient	O
cases	O
and	O
less	O
than	O
2	O
%	O
in	O
control	O
subjects	O
.	O
7	O
,	O
8	O
The	O
study	O
was	O
an	O
unmatched	O
design	O
.	O

The	O
control	O
-	O
to	O
-	O
case	O
ratio	O
for	O
each	O
cancer	O
site	O
was	O
2	O
:	O
1	O
.	O

The	O
desired	O
power	O
to	O
detect	O
a	O
difference	O
was	O
85	O
%	O
with	O
a	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

Minimum	O
sample	O
size	O
was	O
esti	O
-	O
mated	O
to	O
be	O
44	O
patients	O
and	O
88	O
control	O
subjects	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
recruit	O
at	O
least	O
50	O
oral	O
cancer	O
cases	O
,	O
50	O
oro	O
-	O
pharyngeal	O
cancer	O
cases	O
,	O
and	O
100	O
control	O
subjects	O
.	O

Selection	O
of	O
the	O
control	O
group	O

The	O
control	O
subjects	O
were	O
recruited	O
from	O
healthy	O
persons	O
and	O
noncancer	O
patients	O
who	O
visited	O
the	O
clinic	O
for	O
a	O
checkup	O

examination	O
.	O

After	O
the	O
enrollment	O
of	O
cancer	O
cases	O
,	O
subjects	O
who	O
matched	O
the	O
case	O
patients	O
by	O
age	O
(	O
±3	O
years	O
)	O
and	O
sex	O
were	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Specimen	B-HPV_Sample_Type
collection	O
and	O
HPV	O
testing	O

Epithelial	O
cell	O
samples	B-HPV_Sample_Type
were	O
collected	O
by	O
primary	B-HPV_Sample_Collection_Method
tumor	I-HPV_Sample_Collection_Method
brushing	I-HPV_Sample_Collection_Method
in	O
the	O
cancer	O
group	O
and	O
normal	B-HPV_Sample_Collection_Method
mouth	I-HPV_Sample_Collection_Method
and	I-HPV_Sample_Collection_Method
throat	I-HPV_Sample_Collection_Method
mucosa	I-HPV_Sample_Collection_Method
brushing	I-HPV_Sample_Collection_Method
in	O
the	O
control	O
group	O
.	O

The	O
brush	O
device	O
was	O
suspended	O
in	O
PreservCyt®	O
transport	O
medium	O
(	O
Hologic	O
,	O
Inc	O
.	O
,	O
Marlborough	O
,	O
MA	O
)	O
.	O

All	O
specimens	O
were	O
submitted	O
to	O
Chonburi	O
cancer	O
hospital	O
laboratory	O
,	O
and	O
HPV	O
tests	O
were	O
performed	O
within	O
1	O
month	O
after	O
collection	O
.	O

The	O
Cervista®	O
HPV	O
assays	O
(	O
Hologic	O
,	O
Inc	O
.	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
selected	O
for	O
this	O
study	O
mainly	O
because	O
they	O
were	O
used	O
at	O
that	O
time	O
for	O
gynecologic	O
Papanicolaou	O
tests	O
.	O

The	O
Cervista	O
assays	O
use	O
the	O
Invader®	O
technology	O
(	O
Hologic	O
,	O
Inc	O
.	O
,	O
Madison	O
,	O
WI	O
)	O
,	O
a	O
signal	O
amplification	O
method	O
for	O
detec	O
-	O
tion	O
of	O
specific	O
nucleic	O
acid	O
sequences	O
.	O

The	O
Cervista	O
HR	O
-	O
HPV	O
assay	O
detects	O
the	O
presence	O
of	O
14	O
HR	O
-	O
HPV	O
types	O
,	O
namely	O
,	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
66	O
,	O
and	O

The	O
Cervista	O
HR	O
-	O
HPV	O
assay	O
does	O
not	O
differentiate	O
HPV	O
types	O
;	O
thus	O
,	O
Cervista	O
HPV	O
16	O
/	O
18	O
assay	O
was	O
used	O
in	O
conjunc	O
-	O
tion	O
with	O
Cervista	O
HR	O
-	O
HPV	O
assay	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
HPV	O
types	O
16	O
and	O
18	O
.	O
8	O
,	O
9	O
Tests	O
were	O
conducted	O
according	O
to	O
the	O
manufacturer’s	O
guidelines	O
.	O

Inadequate	O
spec	B-HPV_Sample_Type
-	I-HPV_Sample_Type
imens	I-HPV_Sample_Type
were	O
excluded	O
from	O
the	O
study	O
.	O

Smoking	O
,	O
alcohol	O
consumption	O
,	O
and	O
betel	O
quid	O
use	O
criteria	O

Subjects	O
who	O
smoked	O
more	O
than	O
100	O
cigarettes	O
in	O
their	O
lives	O
were	O
categorized	O
in	O
the	O
smoking	O
group	O
.	O

Alcohol	O
drinkers	O
were	O
defined	O
as	O
individuals	O
who	O
had	O
consumed	O
at	O
least	O
one	O
drink	O
per	O
week	O
for	O
at	O
least	O
1	O
year	O
.	O

Subjects	O
who	O
mentioned	O
the	O
daily	O
frequency	O
of	O
betel	O
quid	O
chewing	O
were	O
categorized	O
in	O
the	O
betel	O
quid	O
use	O
group	O
,	O
regardless	O
of	O
duration	O
.	O

Statistical	O
analysis	O

Pearson	O
chi	O
-	O
square	O
or	O
Fisher	O
exact	O
test	O
was	O
used	O
for	O
compar	O
-	O
ing	O
categorical	O
variables	O
between	O
studied	O
groups	O
.	O

Fisher	O
exact	O
test	O
was	O
used	O
if	O
any	O
expected	O
count	O
in	O
the	O
2	O
×	O
2	O
table	O
was	O
less	O
than	O
5	O
.	O

Odds	O
ratios	O
(	O
ORs	O
)	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
the	O
cancers	O
and	O
risk	O
factors	O
.	O

Adjusted	O
ORs	O
were	O
calculated	O
by	O
the	O
Cochran–Mantel–Haenszel	O
method	O
,	O
using	O
SPSS	O
17	O
.	O
0	O
statistical	O
software	O
(	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

A	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

